JohnFPaoliniMDPhD

PubMed

• 16 citations
  Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-c...
  Howard Sofen, Robert Bissonnette, Gil Yosipovitch, Jonathan I Silverberg, Stephen Tyring, Wei Jing Loo, Matthew Zook, Mark Lee, Liangxing Zou, Guang-Liang Jiang, John ...> ;Eclinicalmedicine. 2023 Mar 1
• 3 citations
  Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis.
  Antonio Brucato, Alistair Wheeler, Sushil Allen Luis, Antonio Abbate, Paul C Cremer, Liangxing Zou, Antonella Insalaco, Martin Lewinter, Basil S Lewis, David Lin, Step...> ;Heart. 2023 Jan 27
• 42 citations
  Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
  Maria C Cid, Sebastian H Unizony, Daniel Blockmans, Elisabeth Brouwer, Lorenzo Dagna, Bhaskar Dasgupta, Bernhard Hellmich, Eamonn Molloy, Carlo Salvarani, Bruce C Trap...> ;Annals of the Rheumatic Diseases. 2022 May 1
• 22 citations
  Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with g...
  Marc Corbera-Bellalta, Roser Alba-Rovira, Sujatha Muralidharan, Georgina Espígol-Frigolé, Roberto Ríos-Garcés, Javier Marco-Hernández, Amanda Denuc, Farah Kamberovic, ...> ;Annals of the Rheumatic Diseases. 2022 Apr 1
• 3 citations
  Preclinical Immunopharmacologic Assessment of KPL-404, a Novel, Humanized, Non-Depleting Antagonistic Anti-CD40 Monoclonal Antibody.
  Sujatha Muralidharan, Moses Njenga, Tracy Garron, Kent Bondensgaard, John F Paolini> ;The Journal of Pharmacology and Experimental Therapeutics. 2022 Apr 1
• 3 citations
  Disease and Economic Burden Associated with Recurrent Pericarditis in a Privately Insured United States Population.
  David Lin, François Laliberté, Christine Majeski, Matt Magestro, Dominique Lejeune, Mei Sheng Duh, Michelle Lim-Watson, John F. Paolini> ;Advances in Therapy. 2021 Aug 21
• 2 citations
  Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept.
  David Lin, Allan L. Klein, David Cella, A. Beutler, Fang Fang, Matt Magestro, Paul Cremer, Martin M. LeWinter, Sushil Allen Luis, Antonio Abbate, Andrew Ertel, Leighan...> ;BMC Cardiovascular Disorders. 2021 Apr 21
• 37 citations
  Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polarization
  Micah Belzberg, Martin P. Alphonse, Isabelle D. Brown, Kyle A. Williams, Raveena Khanna, Byron Ho, Shannon Wongvibulsin, Thomas Pritchard, Youkyung S. Roh, Nishadh Sut...> ;The Journal of Investigative Dermatology. 2021 Mar 23
• 50 citations
  Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, ...
  Paul Cremer, Antonio Abbate, Kristin Hudock, Carla McWilliams, Jinesh Mehta, Steven Y. Chang, Calvin C Sheng, Benjamin W. Van Tassell, Aldo Bonaventura, Alessandra Vec...> ;The Lancet. Rheumatology. 2021 Mar 17
• 31 citations
  Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial
  Allan L. Klein, David Lin, Paul Cremer, Saifullah Nasir, Sushil Allen Luis, Antonio Abbate, Andrew W. Ertel, Martin M. LeWinter, A. Beutler, Fang Fang, John F. Paolini> ;Heart. 2021 Mar 1
• 34 citations
  The Role of NLRP3 Inflammasome in Pericarditis: Potential for Therapeutic Approaches.
  Adolfo G Mauro, Aldo Bonaventura, Alessandra Vecchié, Eleonora Mezzaroma, Salvatore Carbone, Pratyush Narayan, Nicola Potere, Antonio Cannatà, John F. Paolini, Rossana...> ;JACC. Basic to Translational Science. 2021 Feb 1
• 49 citations
  Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta.
  Takashi Hashimoto, Leigh A. Nattkemper, Hei Sung Kim, Christina D. Kursewicz, Emilie Fowler, Serena M. Shah, Sonali Nanda, Rachel Fayne, John F. Paolini, Paolo Romanel...> ;Experimental Dermatology. 2021 Jan 11
• 36 citations
  RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with ...
  Allan L. Klein, Massimo Imazio, Antonio Brucato, Paul Cremer, Martin M. LeWinter, Antonio Abbate, David Lin, Alberto Martini, A. Beutler, Steven Chang, Fang Fang, Anai...> ;American Heart Journal. 2020 Jul 14
• 194 citations
  Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial
  Jean-Claude Tardif, Christie M. Ballantyne, Philip J. Barter, Jean-Louis Dasseux, Zahi A. Fayad, Marie-Claude Guertin, John J. P. Kastelein, Constance Keyserling, Heat...> ;European Heart Journal. 2014 Dec 7
• 235 citations
  Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Facto...
  Jonathan L. Halperin, Graeme J. Hankey, Daniel Wojdyla, Jonathan P. Piccini, Yuliya Lokhnygina, Manesh R. Patel, Günter Breithardt, Daniel E. Singer, Richard C. Becker...> ;Circulation. 2014 Jul 8
• 155 citations
  Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibiti...
  Graeme J. Hankey, Susanna R. Stevens, Jonathan P. Piccini, Yuliya Lokhnygina, Kenneth W. Mahaffey, Jonathan L. Halperin, Manesh R. Patel, Günter Breithardt, Daniel E. ...> ;Stroke. 2014 May 1
• 179 citations
  Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antag...
  Shaun G. Goodman, Daniel Wojdyla, Jonathan P. Piccini, Harvey D. White, John F. Paolini, Christopher C. Nessel, Scott D. Berkowitz, Kenneth W. Mahaffey, Manesh R. Pate...> ;Journal of the American College of Cardiology. 2014 Mar 11
• 92 citations
  Niacin Lipid Efficacy Is Independent of Both the Niacin Receptor GPR109A and Free Fatty Acid Suppression
  Brett Lauring, Andrew K.P. Taggart, James R. Tata, Richard L. Dunbar, Luzelena Caro, Kang Cheng, Jayne Chin, Steven L. Colletti, Josee Cote, Sauzanne Khalilieh, Jiajun...> ;Science Translational Medicine. 2012 Aug 22
• 240 citations
  Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF
  Graeme J. Hankey, Manesh R. Patel, Susanna R. Stevens, Richard C. Becker, Günter Breithardt, Antonio Carolei, Hans-Christoph Diener, Geoffrey A. Donnan, Jonathan L. Ha...> ;The Lancet. Neurology. 2012 Apr 1
• 431 citations
  Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
  Keith A.A. Fox, Jonathan P. Piccini, Daniel Wojdyla, Richard C. Becker, Jonathan L. Halperin, Christopher C. Nessel, John F. Paolini, Graeme J. Hankey, Kenneth W. Maha...> ;European Heart Journal. 2011 Oct 1
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
  Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KAA, Ca...> ;N. Engl. J. Med.. 2011-09-08
• 16 citations
  Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome.
  Harold E. Bays, Arvind Shah, Jianxin Lin, Christine McCrary Sisk, John F. Paolini, Darbie Maccubbin> ;Journal of Clinical Lipidology. 2010 Nov 1
• Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipid...
  Shah S, Ceska R, Gil-Extremera B, Paolini JF, Giezek H, Vandormael K, Mao A, McCrary Sisk C, Maccubbin D> ;Int. J. Clin. Pract.. 2010-05-01
• 5 citations
  A comparison of the pharmacokinetics of two different formulations of extended-release niacin.
  Brett Lauring, K. Rosko, Wen-Lin Luo, Larissa Wenning, J. Kissling, K. Roupe, John F. Paolini, John A. Wagner, Eseng Lai> ;Current Medical Research and Opinion. 2009 Sep 29
• 56 citations
  Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without Ischemic Cardi...
  Darbie Maccubbin, Michael J. Koren, Michael H. Davidson, Dov Gavish, Richard C. Pasternak, Geraldine Macdonell, Madhuja Mallick, Christine McCrary Sisk, John F. Paolin...> ;The American Journal of Cardiology. 2009 Jul 1
• Join now to see all

Journal Articles

• Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis  
  Allan L Klein, Paul Cremer, Martin Lewinter, Sushil A Luis, John F Paolini, The New England Journal of Medicine